Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

摘要

Background Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used. Methods Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200?mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS). The primary outcome was change in iFGF23 and cFGF23 from pre-infusion to Day 2 post-infusion. Serum hepcidin, ferritin and phosphate were also measured. Pair-wise comparisons utilised the Wilcoxon rank sum test; linear mixed models with an interaction term for treatment and time evaluated between-group effects. Results Forty-two participants completed the study. In those randomized to FCM ( n =?22), median (interquartile range) values pre-infusion and Day 2, respectively, were 843?pg/mL (313–1922) and 576?pg/mL (356–1296, p =?0.05) for iFGF23, 704RU/mL (475–1204) and 813RU/mL (267–1156, p =?0.04) for cFGF23, and 1.53?mmol/L (1.14–1.71) and 1.37 (1.05–1.67, p =?0.03) for phosphate. These parameters did not change following IS. Both serum ferritin ( p Conclusions Contrary to iron-deficient people with normal renal function, haemodialysis patients given protocol-driven intravenous FCM demonstrated a fall in iFGF23 and a rise in cFGF23, changes not evident with IS. This suggests a differential effect of intravenous iron treatment according to both formulation and renal function. Trial registration Australian and New Zealand Clinical Trials Register ACTRN12614000548639 . Registered 22 May 2014 (retrospectively registered).